Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-DLL4 Antibody (R3W89)

Catalog #:   RHJ65304 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2b
Applications: ELISA, FCM
Accession: Q9NR61
Overview

Catalog No.

RHJ65304

Species reactivity

Human

Host species

Mouse

Isotype

IgG2b

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400

Target

Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NR61

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3W89

Data Image
  • Flow Cytometry
    Flow cytometric analysis of HeLa cells using DLL4 mouse mAb (green) and negative control (red).
References

Targeted delivery of DAPT using dual antibody functionalized solid lipid nanoparticles for enhanced anti-tumour activity against triple negative breast cancer., PMID:39746584

Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials., PMID:39525948

Therapeutic Suppression of Atherosclerotic Burden and Vulnerability via Dll4 Inhibition in Plaque Macrophages Using Dual-Targeted Liposomes., PMID:39392531

Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis., PMID:39390606

Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor., PMID:39375952

The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody., PMID:39046662

Another Notch in the Belt of Rheumatoid Arthritis., PMID:38961731

Molecular hydrogen promotes retinal vascular regeneration and attenuates neovascularization and neuroglial dysfunction in oxygen-induced retinopathy mice., PMID:38915069

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC., PMID:38861293

Endothelial HIF2α suppresses retinal angiogenesis in neonatal mice by upregulating NOTCH signaling., PMID:38770916

ELTD1 Review: New Regulator of Angiogenesis in Glioma., PMID:38559823

DLL4/Notch blockade disrupts mandibular advancement-induced condylar osteogenesis by inhibiting H-type angiogenesis., PMID:38100236

Notch ligands are biomarkers of anti-TNF response in RA patients., PMID:37796367

Incongruence between transcriptional and vascular pathophysiological cell states., PMID:37745941

Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis., PMID:37715566

Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates., PMID:37379368

Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance., PMID:36428773

Notch signaling functions in noncanonical juxtacrine manner in platelets to amplify thrombogenicity., PMID:36190110

Notch Signaling Promotes Mature T-Cell Lymphomagenesis., PMID:36006995

Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study., PMID:35920133

Erratum: Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models., PMID:35812052

Development of anti DLL4 Nanobody fused to truncated form of Pseudomonas exotoxin: As a novel immunotoxin to inhibit of cell proliferation and neovascularization., PMID:35679954

Mycobacterium tuberculosis impedes CD40-dependent notch signaling to restrict Th17 polarization during infection., PMID:35586066

Dll4 Inhibition Promotes Graft Retention in Fat Grafting Enriched with Adipose-Derived Stem Cells., PMID:35579982

Molecular Signature of Antibody-Mediated Chronic Vasculopathy in Heart Allografts in a Novel Mouse Model., PMID:35490714

Anti-Jagged-1 immunotherapy in cancer., PMID:35421813

DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment., PMID:34888208

Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension., PMID:34739767

Delta-like 1-Expressing Cells at the Gland Base Promote Proliferation of Gastric Antral Stem Cells in Mouse., PMID:34438113

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors., PMID:34315767

NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells., PMID:34095881

Porphyromonas gingivalis lipopolysaccharide promotes T-hel per17 cell differentiation by upregulating Delta-like ligand 4 expression on CD14+ monocytes., PMID:33981487

Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer., PMID:33628824

Anti-DLL4 ameliorates toluene diisocyanate-induced experimental asthma by inhibiting Th17 response., PMID:33578263

NOTCH signalling in ovarian cancer angiogenesis., PMID:33490217

CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn's disease., PMID:33436852

Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia., PMID:33408769

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models., PMID:33383646

O-Fucose and Fringe-modified NOTCH1 extracellular domain fragments as decoys to release niche-lodged hematopoietic progenitor cells., PMID:33351914

Dll4 Blockade Promotes Angiogenesis in Nonhealing Wounds of Sox7-Deficient Mice., PMID:33095124

Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models., PMID:32905508

Unique Cholangiocyte-Targeted IgM Autoantibodies Correlate With Poor Outcome in Biliary Atresia., PMID:32767570

Reciprocal communication between astrocytes and endothelial cells is required for astrocytic glutamate transporter 1 (GLT-1) expression., PMID:32650029

DLL4 restores damaged liver by enhancing hBMSC differentiation into cholangiocytes., PMID:32622343

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer., PMID:32580836

CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells., PMID:32457739

Heritable modifiers of the tumor microenvironment influence nanoparticle uptake, distribution and response to photothermal therapy., PMID:32373218

CAFs-derived MFAP5 promotes bladder cancer malignant behavior through NOTCH2/HEY1 signaling., PMID:32293074

Dll4 Suppresses Transcytosis for Arterial Blood-Retinal Barrier Homeostasis., PMID:32078435

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial., PMID:32037195

Datasheet

Document Download

Anti-DLL4 Antibody (R3W89).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-DLL4 Antibody (R3W89) [RHJ65304]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only